Sheng X, Yan X, Wang L, Shi Y, et al. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res 2021;27:43-51.
PMID: 33109737